Biotech Daily

Thursday July 2, 2026

Daily news on ASX-listed biotechnology companies

*** ASX FLAT, BIOTECH UP: DIMERIX UP 16%; CURVEBEAM DOWN 20%**

*** IMRICOR FDA NORTHSTAR, VISION-MR PAEDIATRIC HEART LABEL**

*** TELIX, FDA ALIGN ON PHASE III TLX591-Tx CONTINUATION**

*** CYCLOPHARM UNAUDITED H1 REVENUE UP 11% TO $17m**

*** LUMOS CLOSES $5m TENMILE, RYDER LOAN; REPAYS $1m**

*** GENETIC SIGNATURES 'UNAWARE' OF BCAL 10% CLAIM**

*** FLOREY: FEDERAL $4.6m FOR PARKINSON'S DISEASE STEM CELL TRIAL**

*** NOXOPHARM: FEDERAL $1m FOR HUDSON SOFRA PROGRAM**

*** ONCOSIL SELECTED FOR 'PULSE' PHASE II PANCREATIC CANCER STUDY**

*** STARPHARMA PRE-CLINICAL DEP HER2 DATA BACKS PHASE I TRIAL**

*** LIFE SCIENCES QUEENSLAND $37k GENE AWARDS**

*** ECHO IQ LICENCES ADVARA ECG DATA FOR A.I.**

*** ISLAND SINGAPORE ISLA-101 PATENT**

*** NEUROTECH: US ALLOWS NTI164 PATENTS**

*** OSTEOPORE COMPLETES VENTRICULAR DRAIN GUIDE PROJECT**

*** RHYTHM MARKET RESEARCH ON COLOSTAT USE CASES**

*** ADALTA: OKTOPI A.I. FOR MEDICAL, BUSINESS DEVELOPMENT**

*** BLACKROCK TAKES 8% OF COCHLEAR**

*** FIL (FIDELITY) REDUCES TO 6% OF CYNATA**

*** CLINUVEL EXTENDS M-D DR PHILIPPE WOLGEN EMPLOYMENT**

MARKET REPORT

The Australian stock market edged up 0.02 percent on Thursday July 2, 2026, with the ASX200 up 1.6 points to 8,724.5 points. Twenty-one of the Biotech Daily Top 40 companies were up, nine fell, nine traded unchanged and one was untraded.

Dimerix was the best, up 3.5 cents or 16.3 percent to 25 cents, with 9.1 million shares traded. Avita and EBR climbed more than 15 percent; Proteomics was up 14.3 percent; Imricor improved 12.5 percent; Actinogen and Syntara were up more than nine percent; Optiscan and Prescient rose eight percent or more; Medical Developments was up 7.3 percent; Atomo climbed 5.9 percent; Saluda was up 4.2 percent; Racura and Resmed rose more than three percent; Clarity, Cochlear, Emvision, Polynovo and Pro Medicus were up more than one percent; with 4D Medical, Aroa, Mesoblast, Nanosonics and Telix up by less than one percent.

Curvebeam led the falls, down 0.5 cents or 20 percent to two cents, with 3.6 million shares traded. Compumedics lost 10.7 percent; Micro-X and Paradigm fell more than five percent; Botanix was down 4.55 percent; Imugene and Neuren shed more than three percent; Clinuvel and Immutep lost more than one percent; with CSL down 0.5 percent.

IMRICOR MEDICAL SYSTEMS

Imricor says it has US Food and Drug Administration 510(k) clearance for a paediatric label expansion of its Northstar heart mapping system and Vision-MR diagnostic catheter.
Earlier this year, Imricor said it had FDA 510(k) clearance for its Vision-magnetic resonance (MR) diagnostic catheter, its first FDA clearance; and later, said it had FDA 510(k) clearance for its Northstar 3-dimensional magnetic resonance imaging (MRI) mapping and guidance system (BD: Jan 18, 29, 2026).
Today, the company said that the clearances allowed it to market Northstar and Vision-MR diagnostic catheter for use with patients of any age, including children and young adults treated at more than 250 children's hospitals in the US.
Imricor said paediatric patients who may benefit from interventional magnetic resonance (IMR) procedures include those born with congenital heart defects who require several cardiac catheterizations at a young age.
The company said the clearances were "another important step in the company's US commercialization strategy".
Imricor said that children's hospitals often had "a strong interest in reducing radiation exposure and the use of contrast dyes for their patients, and as a navigation system for use in IMR procedures, Northstar may be well suited to adapt and improve IMR procedure workflows currently performed with only stock magnetic resonance imaging system interfaces".
Imricor executive chair Steve Wedan said the company cared "about children, and we don't shy away from delivering our products to all patient segments who can benefit from radiation-free [interventional magnetic resonance] procedures".
"Having experienced first-hand, the paediatric use of products I personally developed throughout my career, I can say there is something particularly rewarding about providing technology to help infants and young children," Mr Wedan said.
"Changing the world of interventional medicine for doctors and patients means changing it for all doctors and all patients," Mr Wedan said.
Imricor was up 22.5 cents or 12.5 percent to $2.03 with 1.6 million shares traded.

TELIX PHARMACEUTICALS

Telix says it has aligned with the US Food and Drug Administration on the continuation of its 520-patient, phase III trial of TLX591-Tx prostate cancer therapy.
Last year, Telix said it completed the 36-patient safety portion of its 520-patient, phase III study of TLX591-Tx for prostate cancer; and earlier this year, said the lead-in showed an acceptable safety and tolerability profile (BD: Dec 18, 2025, Mar 10, 2026).
Today, the company said the FDA confirmed the safety data from the led-in cohort of the study was “sufficient to enable progression to part two … in which TLX591-Tx is administered in two doses, 14 days apart, in combination with one of three randomized standard-of-care therapies: abiraterone, enzalutamide or docetaxel”.
Telix said the FDA also aligned on the clinical trial protocol, statistical analysis plan and ongoing safety monitoring plan of the second part of the study.
The company said the result was “a consistent framework for study execution as enrolment continues internationally and expands into the US”.
Telix chief medical officer Dr David Cade said the FDA feedback was “an excellent outcome that enables submission of our [investigational new drug] amendment for initiation of part two of [the trial] … in the US”.
“Part two continues to enrol strongly in regions where recruitment is open,” Dr Cade said.
Telix was up 16 cents or 0.9 percent to $17.18 with 3.55 million shares traded.

CYCLOPHARM

Cyclopharm says unaudited revenue for the six months to June 30, 2026 was up 11.0 percent to about $17.1 million, compared to the previous corresponding period.
Cyclopharm said revenue from Technegas lung imaging system sales were up 73 percent to $2.1 million in the US, with a 13 percent increase in Technegas sales outside the US to $7.2 million and third-party distribution revenue flat at $7.8 million.
The company said each revenue-generating installation did “not represent a one-time sale [but] … a recurring, sustained consumable revenue stream that compounds with every additional site added and every additional procedure performed at existing sites”.
Cyclopharm said it had 70 primary US sites generating revenue, linked to 429 contracted affiliated network locations, increasing recurring revenue potential and incremental annuity revenue potential that could be activated without the lead time associated with an additional network relationship.
The company said it had unaudited cash and cash equivalents of about $12.2 million at June 30, 2026 and that it believed it had “passed peak cash burn”.
Cyclopharm was unchanged at 50 cents.

LUMOS DIAGNOSTICS

Lumos says it has closed its $5.0 million loan with Tenmile Ventures and Ryder Capital Management, with the $1.0 million drawn-down repaid in full, including interest.
Last year, Lumos said it had a $5.0 million loan from shareholders Dr Andrew ‘Twiggy’ Forest’s Tenmile Ventures and Ryder Capital Management to fund its progression towards US Food and Drug Administration clinical laboratory improvement amendments (CLIA) waiver for its Febridx finger-prick blood test (BD: Jul 17, Sep 9, 2025).
Earlier this year, the company said the FDA granted a CLIA waiver for its Febridx test, and that it would raise $22 million (BD: Mar 27, 2026).
Today, Lumos said the $1.0 million was repaid using the placement funds raised.
Lumos was unchanged at 10.5 cents.

BCAL DIAGNOSTICS, GENETIC SIGNATURES

Genetic Signatures says it was not aware of Bcal's claim to buy its shares until it saw the Bcal announcement to the ASX.

At 2.41pm, Genetic Signatures said "it was not notified in advance of Bcal's announcement and had no prior knowledge of the proposed acquisition of shares".

At 10.04am, Bcal said it would acquire 23,173,644 Genetic Signatures shares, or 10.2 percent, for $1,390,119, or six cents a share.

Bcal said the rationale for the acquisition was "the potential to gain access to Genetic Signatures' platform, its established commercial operations, active paying customers in Australia, the UK and the US, and international market access channels".

The company said the investment provided "an opportunity to add an additional diagnostics pillar to Bcal's existing focus on early cancer detection".

Bcal said "Genetic Signatures' infectious disease [polymerase chain reaction] platform is complementary to Bcal's oncology liquid biopsy and breast cancer diagnostics portfolio" and its laboratory, manufacturing, distribution and support infrastructure had potential for broader commercialization.

Bcal chair Jayne Shaw said Genetic Signatures would give Bcal "exposure to an additional diagnostics pillar in infectious disease, while supporting our broader strategy to build a stronger diagnostics platform across cancer and molecular testing".

Genetic Signatures said it "has not received any approach, proposal or communication from Bcal regarding any strategic transaction, acquisition proposal or other corporate activity involving the company" and at the time of its announcement, "no substantial holder notice has been received by [Genetic Signatures] or lodged with the ASX".

Genetic Signatures said it was not in a position to comment on Bcal's intentions and it wanted "to reassure shareholders, customers, employees and other stakeholders that [it] continues to operate in the ordinary course of business".

Genetic Signatures said it would "monitor any developments in this matter".

In their most recent Appendix 4C quarterly reports for the three months to March 31, 2026 Bcal said it had $2,364,000 in cash with 1.6 quarters of funding; and Genetic Signatures said it had $25,695,000 in cash with 7.3 quarters of funding.

On Monday, Bcal said it had commitments for an additional $4.9 million under its $10 million convertible note facility with an unnamed lender (BD: Jun 29, 2026).

Last year, Bcal said it would raise $5 million in notes at 10 percent annual interest, for an unnamed lender, with the option for up-to $10 million, (BD: Oct 20, 2025).

Bcal was unchanged at 7.1 cents.

Genetic Signatures fell 0.3 cents or 4.4 percent to 6.5 cents.

THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH

The Florey Institute says the Federal Government will support a five-year, $4.6 million research program of stem cell therapy for reversing Parkinson's disease.

The Florey said the program would include pre-clinical studies with Monash University, the University of Sydney, the Walter and Eliza Hall Institute and Melbourne's Icamuno Biotherapeutics.

The Institute said the program was supported by funding from the Medical Research Future Fund and involved the transplantation of "dopamine-releasing neurons with the potential to repair brain damage caused by Parkinson's disease, without the need for long-term immuno-suppression, a key limitation of other stem cell approaches".

The Florey said the final stage of the program would be a clinical trial led by the Royal Melbourne Hospital, with expansion to the Alfred Hospital.

NOXOPHARM

Noxopharm says the Hudson Institute of Medical research has a $1 million Federal Government grant to fund a project involving its Sofra platform.
Noxopharm said the Hudson received funds from the Medical Research Future Fund for a three-year project using its Sofra oligonucleotides to treat birth injuries by incorporating them in a topical cream designed to reduce inflammation associated with pelvic floor disorders in women and allow for tissue regeneration.
Noxopharm was up 0.7 cents or 8.2 percent to 9.2 cents.

ONCOSIL MEDICAL

Oncosil says its phosphorous-32 device has been selected for use in a 120-patient, 'Pulse', phase II study for pancreatic cancer at five European sites.
Oncosil said the 'Pulse' study was part of the Palacros, or 'Prioritizing Multimodal Surgical Care for Patients with Locally Advanced Pancreatic Cancer Across Europe' consortium, funded by the EU under the Horizon Europe research and innovation program to support clinical trials, expand training and improve patient selection.
The company said it would participate in the Palacros program through its 'Pulse', phase II trial of its device in patients following chemotherapy, and would provide its devices in-kind, with no other study-related costs applicable to Oncosil.
Oncosil said the structure allowed it to generate a clinical dataset in locally advanced pancreatic cancer without site, monitoring, regulatory, data-management and other operating costs that a company-sponsored trial of comparable size and duration would require, saving about $9 million relative to an equivalent company-led trial.
The company said study endpoints included local progression-free survival, overall survival, quality-of-life, conversion to surgery, safety and health economic analyses.
Oncosil managing-director Nigel Lange said being selected to participate in Palacros was "an important validation for Oncosil … [and was] funded via a grant from the European Union, is an academically driven European consortium bringing together a select group of the world's leading pancreatic cancer centres".
Oncosil was up 5.5 cents or 7.3 percent to 81 cents.

STARPHARMA HOLDINGS

Starpharma says DEP HER2-lutetium pre-clinical data shows "highly favorable bio-distribution and encouraging anti-tumor activity", supporting its planned phase I study.
Previously, Starpharma said its dendrimer enhanced product (DEP) diagnostic was designed to diagnose, stage and monitor human epidermal growth factor receptor 2 (HER2) positive cancers with greater sensitivity" (BD: Jul 21, 2023).
Today, the company said the data showed DEP HER2 showed "strong tumor uptake and retention, low kidney accumulation and short blood circulation time in pre-clinical HER2-positive cancer models, supporting the target profile for radio-ligand therapy".
The company said DEP HER2 had "statistically significant anti-tumor activity and survival benefit in pre-clinical models, with effects comparable to Enhertu … in those models".
Starpharma said it had filed a patent covering its DEP dendrimer technology in radio-ligand therapy, but did not disclose the jurisdiction, title or duration if approved.
The company said its planned first-in-human, 15-patient, phase I study of DEP-HER2 was expected to begin by 2027 to assess safety, tolerability, pharmaco-kinetics, biodistribution and organ radiation dosimetry.
Starpharma was unchanged at 71 cents.

LIFE SCIENCES QUEENSLAND

Life Sciences Queensland says nominations are open for seven ‘Gene Awards’ worth $37,000 for Queensland life sciences researchers, innovators and organizations.
Life Sciences Queensland said that it was the 15th ‘Gene Awards’ and that it was the first year it would award a $25,000 ‘Bio-Innovation Bursary’ to support emerging and mid-career talent and “recognize a project with strong potential to advance innovation, collaboration, commercialization and broader sector impact across Queensland”.
The organization said other awards included $2,000 in prize money each for the Cytiva Company of the Year, KE Select Services Excellence, McCullough Robertson Industry Excellence, Merck Life Science’s Science and Regional Service Award, QIMR Berghofer Woman of Influence Award and Radium Capital Emerging Innovator Award.
LSQ said the awards would be announced on September 11, with registrations at: https://bit.ly/4y0O31g; nominations at: https://www.lsq.com.au/news/gene-awards-2025

ECHO IQ

Echo IQ says it will licence a 500,000 to 1,000,000 dataset of echo-cardio-graphic (ECG) studies and images from Advara Heartcare to train artificial intelligence (A.I.) models.
Echo IQ said Advara was “Australia's largest private cardio-vascular diagnostics provider” and operated a national network of cardiovascular clinics and diagnostic facilities, delivering echo-cardio-graphy and other cardiac imaging services.
The company said it would receive access to a substantial dataset of de-identified echo-cardio-graphy studies and associated clinical information from Advara.
Echo IQ said initial delivery of data was subject to ethics approval and agreement on data quality specifications and would be used to “significantly enhance Echo IQ's ability to develop, train and validate future A.I. models”.
The company said “large-scale imaging datasets and longitudinal clinical outcomes data represent a significant competitive advantage and further strengthens the company's position as a leading developer of A.I.-enabled cardiovascular diagnostics”.
Echo IQ managing-director Dustin Haines said securing access to a dataset of this scale was “strategically important for Echo IQ and represents a significant enhancement to our long-term A.I. development capabilities”.
Echo IQ was up 13 cents or eight percent to $1.75 with 10.7 million shares traded.

ISLAND PHARMACEUTICALS

Island says the Intellectual Property Office of Singapore has granted a patent protecting the use of ISLA-101 for treating flavivirus and Chikungunya virus infections.
Island said the patent, titled ‘Method of Viral Inhibition’ would protect its intellectual property until April 16, 2034, including the use of ISLA-101 in the absence of another anti-viral agent for the treatment of flavivirus infections including dengue and Chikungunya.
Island was up 1.5 cents or four percent to 39 cents.

NEUROTECH INTERNATIONAL

Neurotech says the US Patent and Trademark Office has allowed patents relating to its NTI164 product for reducing neuro-inflammation in autism spectrum disorder.
Neurotech said the patents, titled ‘Compositions and Methods for Treating Neurological Disorders’ if approved would protect its intellectual property until 2042.
Neurotech was up 0.3 cents or 21.4 percent to 1.7 cents with 7.4 million shares traded.

OSTEOPORE

Osteopore says it has completed development of an intra-operative external ventricular drain guide for neurosurgery with Singapore's National University Hospital.

Earlier this year, Osteopore said with the National University Hospital it would develop an intraoperative, surgical guide for external ventricular drain placement for neurosurgery (BD: Mar 10, 2026).

At the time, the company said an external ventricular drain (EVD) was a temporary catheter inserted into the brain's fluid spaces to drain excess cerebrospinal fluid or blood and relieve pressure after stroke, trauma or haemorrhage.

Today, Osteopore said the collaboration included a design and prototyping phase followed by simulated testing of the drain guide in dry bone models.

The company said the simulated testing showed "high precision outcomes, scoring more than 97 percent precision across 40 unique trajectories into the target brain fluid space of 10 patient specific dry bone models".

Osteopore said "in all of the 40 cases, a modified Osteoplug-C, one of Osteopore's highly used neurosurgery implants, was paired with this EVD guide [and that] this EVD guide is meant to be used together with the Osteoplug-C".

Osteopore was unchanged at 0.5 cents with 13.9 million shares traded.

RHYTHM BIOSCIENCES

Rhythm says it has completed in-field market research "confirming the existence of colonoscopy backlogs in 10 institutions that could be addressed with Colostat".

Rhythm said it had begun "a targeted email marketing campaign through the Australian Doctor Group platform, designed to reach more than 20,000 authenticated [general practitioner] subscribers across the Eastern States of Australia" to increase awareness of Colostat among clinicians for blood-based colorectal cancer triage testing.

Rhythm was unchanged at 10 cents.

ADALTA

Adalta says it has an agreement to use the Melbourne-based Oktopi's artificial intelligence (A.I.)-enabled software for medical and business development.

Adalta said the software collaboration was part of its strategy to improve "the quality, efficiency and probability of success in its research and business development decisions".

The company said Oktopi would "focus and prioritize research planning and due diligence, helping Adalta make better development and in-licencing decisions and scale more easily" but did not disclose the commercial terms of the agreement.

Adalta was unchanged at 0.4 cents with 6.7 million shares traded.

COCHLEAR

Blackrock Group says it has increased its substantial shareholding in Cochlear from 4,712,707 shares (7.13%) to 5,723,271 shares (8.21%).

In a 440-page substantial shareholder notice, New York's Black Rock said it bought, sold and transferred shares between April 26, 2021 and June 29, 2026.

Cochlear was up $1.90 or 1.6 percent to $120.35 with 611,050 shares traded.

CYNATA THERAPEUTICS

FIL (Fidelity Limited) says it has reduced its substantial shareholding in Cynata from 20,967,806 shares (8.83%) to 15,526,501 shares (6.38%).

The Hong Kong-based FIL said that it bought 529,817 shares on May 5, 2026 at 25 cents a share and sold 286,844 shares on June 26 at 1.4 cents a share and a further 5,684,278 shares on June 29, 2026 for at 1.28 cents a share.

Last month, Cynata fell 94.2 percent on its 440-patient, phase III CYP-004 for knee osteo-arthritis trial showing “no statistically significant differences” between active and control groups; and following its 65-patient, phase II trial of CYP-001 for high-risk acute graft versus host disease showing “no significant differences between” active and control groups (BD: Jun 17, 19, 2026).

Cynata was unchanged at 1.4 cents with 1.8 million shares traded.

CLINUVEL PHARMACEUTICALS

Clinuvel says it has agreed to extend the current employment agreement with managing-director Dr Philippe Wolgen.

In a document on the ASX titled, ‘Clinuvel Extends Employment Agreement with CEO’ dated April 1, 2022, the company did not disclose the details of Dr Wolgen’s pay.

In its 2025 annual report, Clinuvel said Mr Wolgen’s gross salary for 2024-’25 was $1,877,394 with total remuneration including share-based payments of $5,241,748.

Today, the company said Dr Wolgen’s short-term remuneration of 100 percent of his fixed base pay remained unchanged, with all retention payments removed and no long-term incentive implemented.

Clinuvel fell 16 cents or 1.5 percent to $10.26.